Marco Floridia

Dr. Marco Floridia

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in Pharmacological Research
Verified
Journal Article
Closed access
MFMarco Floridia
Marco Floridia
MGMarina Giuliano
Marina Giuliano
LPL Palmisano
L Palmisano
SVS Vella
S Vella

1 August 2000 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
KVKristien Van Vaerenbergh
Kristien Van Vaerenbergh
KLKristel Van Laethem
Kristel Van Laethem
JAJan Albert
Jan Albert
CBCharles A. B. Boucher
Charles A. B. Boucher
BCBonaventura Clotet
Bonaventura Clotet
AVAnne-Mieke Vandamme
Anne-Mieke Vandamme
The prevalence and the genotypic and phenotypic characteristics of multinucleoside-resistant (MNR) human immunodeficiency virus type 1 (HIV-1) variants in Europe were investigated in a multicenter study that involved centers in nine European countries. Study samples ( n = 363) collected between 1991 and 1997 from patients exposed to two or more nucleoside analogue reverse transcriptase inhibitors (NRTIs) and 274 control samples from patients exposed to no or one NRTI were screened for two marker mutations of multinucleoside resistance (the Q151M mutation and a mutation with a 2-amino-acid insertion at codon 69, T69S-XX). Q151M was identified in six of the study samples (1.6%), and T69S-XX was identified in two of the study samples (0.5%; both of them T69S-SS), but both patterns were absent among control samples. Non-NRTI (NNRTI)-related changes were observed in viral strains from two patients, which displayed the Q151M resistance pattern, although the patients were NNRTI naive. The patients whose isolates displayed multinucleoside resistance had received treatment with zidovudine and either didanosine, zalcitabine, or stavudine. Both resistance patterns conferred broad cross-resistance to NRTIs in vitro and a poor response to treatment in vivo. MNR HIV-1 is found only among multinucleoside-experienced patients. Its prevalence is low in Europe, but it should be closely monitored since it seriously limits treatment options.

1 August 2017 in The Lancet HIV
Verified
Journal Article
Open access
NPNicholas I Paton
Nicholas I Paton
CKCissy Kityo
Cissy Kityo
JTJennifer Thompson
Jennifer Thompson
INImmaculate Nankya
Immaculate Nankya
LBLeonard Bagenda
Leonard Bagenda
JVJ Villacian
J Villacian
Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. We aimed to assess the association between the activity, predicted by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients infected with HIV. We did an observational analysis of additional data from a published open-label, randomised trial of second-line ART (EARNEST) in sub-Saharan Africa. 1277 adults or adolescents infected with HIV in whom first-line ART had failed (assessed by WHO criteria with virological confirmation) were randomly assigned to a boosted protease inhibitor (standardised to ritonavir-boosted lopinavir) with two to three NRTIs (clinician-selected, without resistance testing); or with raltegravir; or alone as protease inhibitor monotherapy (discontinued after week 96). We tested genotypic resistance on stored baseline samples in patients in the protease inhibitor and NRTI group and calculated the predicted activity of prescribed second-line NRTIs. We measured viral load in stored samples for all patients obtained every 12-16 weeks. This trial is registered with Controlled-Trials.com (number ISRCTN 37737787) and ClinicalTrials.gov (number NCT00988039). Baseline genotypes were available in 391 (92%) of 426 patients in the protease inhibitor and NRTI group. 176 (89%) of 198 patients prescribed a protease inhibitor with no predicted-active NRTIs had viral suppression (viral load <400 copies per mL) at week 144, compared with 312 (81%) of 383 patients in the protease inhibitor and raltegravir group at week 144 (p=0·02) and 233 (61%) of 280 patients in the protease inhibitor monotherapy group at week 96 (p<0·0001). Compared with results with no active NRTIs, 95 (85%) of 112 patients with one predicted-active NRTI had viral suppression (p=0·3) and 20 (77%) of 26 patients with two or three active NRTIs had viral suppression (p=0·08). Over all follow-up, greater predicted NRTI activity was associated with worse viral load suppression (global p=0·0004). Genotypic resistance testing might not accurately predict NRTI activity in protease inhibitor-based second-line ART. Our results do not support the introduction of routine resistance testing in ART programmes in low-income settings for the purpose of selecting second-line NRTIs. European and Developing Countries Clinical Trials Partnership, UK Medical Research Council, Institito de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, WHO, Merck.

1 July 2006 in The Lancet
Verified
Journal Article
Closed access
ICINITIO Trial International Co-ordinating Committee
INITIO Trial International Co-ordinating Committee
PYP Yeni
P Yeni
DCD A Cooper
D A Cooper
JAJ P Aboulker
J P Aboulker
ABA G Babiker
A G Babiker
BSB Salzberger
B Salzberger

1 January 1998 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
SVStefano Vella
Stefano Vella
MFMarco Floridia
Marco Floridia

26 April 2006 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
PVP. Villani
P. Villani
MFMarco Floridia
Marco Floridia
MPMaria Franca Pirillo
Maria Franca Pirillo
MCM. Cusato
M. Cusato
ETE. Tamburrini
E. Tamburrini
MRM. Regazzi
M. Regazzi